Trial Profile
A phase II study investigating carboplatin, pemetrexed, and bevacizumab followed by bevacizumab and erlotinib as maintenance therapy in patients with non-squamous non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Bevacizumab; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Jan 2016 New trial record